Background and objective: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis (IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study was to assess the effect of ambulatory oxygen on dyspnea in IPF patients without resting hypoxemia but with desaturation on exertion. Methods: This was a double-blind, placebo-controlled, randomized crossover trial of ambulatory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial oxygen (PaO 2 ) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at 4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests. Results: Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco) of 57.0 (13.3) %, and PaO 2 of 72.5 (5.4) mm Hg were recruited. No significant differences in dyspnea were observed between ambulatory oxygen and air at each time point. However, some patients showed improvement in dyspnea with oxygen on an individual basis.
Summary
Background and objective: The effects of ambulatory oxygen for idiopathic pulmonary fibrosis (IPF) patients without resting hypoxemia have not been elucidated. The purpose of this study was to assess the effect of ambulatory oxygen on dyspnea in IPF patients without resting hypoxemia but with desaturation on exertion.
Methods: This was a double-blind, placebo-controlled, randomized crossover trial of ambulatory oxygen versus ambulatory air. Patients with IPF who had a partial pressure of arterial oxygen (PaO 2 ) between 60 mm Hg and 80 mm Hg at rest, and desaturation of 88% or less in a room-air 6-min walk test were eligible. Patients underwent a standardized 6-min walk test and a 6-min free walk test under each ambulatory gas. Oxygen and air were provided at 4 L/min intranasally. Dyspnea was evaluated immediately, 1, and 2 min after the tests. Results: Twenty patients (16 men), with a mean age of 73.5 (SD 4.1) years, % predicted forced vital capacity (FVC) of 71.0 (13.3) %, % predicted diffusion capacity for carbon monoxide (DLco) of 57.0 (13.3) %, and PaO 2 of 72.5 (5.4) mm Hg were recruited. No significant differences in dyspnea were observed between ambulatory oxygen and air at each time point. However, some patients showed improvement in dyspnea with oxygen on an individual basis.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease of unknown cause characterized by the histopathological pattern of usual interstitial pneumonia [1] . The prognosis is poor, being roughly 3e4 years [2, 3] , and no pharmacological therapies have been shown to improve survival. As the disease progresses, dyspnea becomes severe and activity of daily living can often seriously deteriorate in IPF patients. When patients become hypoxemic (partial pressure of arterial oxygen [PaO 2 ] < 55 mmHg), long-term oxygen therapy (LTOT) is usually recommended. The prescription of LTOT was originally based on 2 studies that demonstrated mortality benefit of LTOT for patients with chronic obstructive pulmonary disease (COPD) [4, 5] . A Cochrane review that summarized the effect of LTOT including later studies also concluded that LTOT improved survival in COPD patients with resting hypoxemia [6] . Given these reports, it seems reasonable that IPF patients who have resting hypoxemia undergo LTOT, although mortality benefit has not been specifically demonstrated in IPF [7] .
In general practices, clinicians often prescribe ambulatory oxygen for IPF patients without resting hypoxemia, who experience hypoxemia during exercise or activities of daily living. Actually, more severe desaturation occurs in IPF patients when exercising than in COPD patients [8] . However, the effects of ambulatory oxygen for IPF patients without resting hypoxemia but with exertional desaturation have not been elucidated. Daily dyspnea is the major contributing factor to the health-related quality of life of these patients [9] and, furthermore, one of the prognostic factors in IPF [10] . If oxygen alleviates dyspnea, it might be possible to not only improve health-related quality of life but also prolong longevity in IPF patients.
To assess the effect of oxygen on dyspnea after a 6-min walk test in IPF patients without resting hypoxemia, we designed a double-blind, placebo-controlled, randomized crossover trial using ambulatory oxygen and ambulatory air.
Materials and methods

Patients
Patients with IPF were recruited from the Department of Respiratory Medicine and Allergology, Kinki University Faculty of Medicine in Osaka-sayama, Japan. Eligible patients were aged !20 yrs, with a PaO 2 between 60 mmHg and 80 mmHg at rest, and with desaturation of 88% or less in a room-air 6-min walk test. Disease was diagnosed according to the criteria of the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Association for the diagnosis of IPF [1] .
Patients were excluded if they had infection or acute worsening of the disease within 3 months or unstable comorbid illnesses. We also excluded those patients who could not undertake pulmonary function tests and 6-min walk tests, those on more than 10 mg/day corticosteroids, and those who were receiving LTOT for the purpose of mortality reduction.
Written informed consent was obtained from every patient. The study protocol was approved by the ethics committee of Kinki University Faculty of Medicine (No. 22e58).
Study design
The study was a double-blind, placebo-controlled, randomized crossover trial using ambulatory oxygen and ambulatory air. Patients underwent 2 different types of 6-min walk tests on the first day under either ambulatory intranasal oxygen or air: one was an ordinary standardized test with an enthusiastic walk and the other was a free walk test with a comfortable pace. Then, the patients were crossed over to the other type of intranasal gas and underwent the same walk tests on the next day. Allocation was concealed from both the patients and the physicians who supervised the walk tests. The order of pairs was randomly determined. Ambulatory oxygen and placebo air were provided at a rate of 4 L/min through nasal cannulas using a demand oxygen delivery system (Fukuda Denshi, Inc., Tokyo, Japan) [11, 12] .
Oxygen and placebo air were supplied by Fukuda Densi, Inc., Tokyo, Japan. The shapes of the oxygen and placebo air cylinders were completely the same but the colors were different according to the Japanese law for medical gases (black for oxygen and dark green for air). However, each cylinder was covered with an identical sack so that the subjects and physicians remained blinded to the treatment group.
Outcomes
Patients completed 2 walk tests on the first and second days of the study. The first test was an ordinary standardized 6-min walk test, which was conducted according to the ATS statement [13] . Briefly, patients were tested under standardized conditions by trained physicians while inhaling ambulatory oxygen or placebo air. Patients wore a pulse oximetry sensor (WristOxä, NONIN, Inc., Minneapolis, U.S.A.) on their wrist and baseline oxygen saturation and heart rate were recorded by the coordinator; these results were concealed from the physicians who performed the tests. Patients were instructed to walk as fast as possible up and down a 30 m corridor for 6 min. The distance the patients could walk, as well as oxygen saturation and heart rate immediately, 1, and 2 min after the test were recorded. Furthermore, patients were asked to rate their dyspnea immediately, 1, and 2 min after the test, using the modified Borg scale, by selecting a number from 0 to 10, with 0 being no appreciable dyspnea and 10 being maximal sustainable dyspnea [14] . Physicians did not walk with the patients to minimize encouraging effects. A warm-up test was not performed because all patients had already undertaken an ordinary 6-min walk test without any ambulatory gas before the study walk, in order to confirm desaturation.
The second test was a 6-min free walk test in which the patients were instructed to walk at a pace that "they found comfortable and would use to walk on a day to day basis". The same values as those measured for the ordinary 6-min walk test were recorded.
Data analysis
Continuous variables were summarized as mean (standard deviation [SD] ). Categorical variables were summarized as counts and percentages. Dyspnea and leg fatigue after walk tests, assessed with the modified Borg scale [14] , were analyzed as continuous variables. An unpaired t test was performed to make comparisons between the oxygen and placebo air group.
An original sample size of 20 was determined to detect a reduction of 1 in the modified Borg scale after walk tests, which has been reported to be the minimal clinically important difference [15] , with oxygen as compared to placebo air. The sample size provided a statistical power of 80%, allowing for a type I error of 0.05.
All statistical analyses were performed using the PASW statistical package, version 18 (SPSS Japan Inc., Tokyo, Japan). A P value less than 0.05 was considered statistically significant.
Results
Patients
All 20 patients who were identified as eligible between February 2011 and April 2012 were included in the study (Fig. 1) . The characteristics of these 20 patients are shown in Table 1 . The mean age was 73.5 years and 80% of the patients (16/20) were male. No patients were already receiving LTOT for mortality reduction or symptom relief. The mean forced vital capacity (FVC) at recruitment was 2.1 L (71% predicted), mean diffusion capacity for carbon monoxide (DLco) was 8.3 mL min À1 mmHg À1 (57% predicted), and mean PaO 2 was 73 mm Hg. The results of an ordinary 6-min walk test conducted before the study without any ambulatory gases included a mean walk distance of 400 m, a mean desaturation of 80%, and a mean dyspnea rating assessed with the modified Borg scale of 5.7. There were no statistically significant differences in baseline variables between those who underwent walk tests with oxygen first and those who received placebo air first.
Outcomes of walk tests
In the ordinary standardized 6-min walk test, ambulatory oxygen significantly improved oxygen saturation immediately, 1, and 2 min after the test (Table 2) . However, oxygen did not significantly improve walk distance or other walk test outcomes including heart rate, dyspnea rating, and leg fatigue. The results of the 6-min free walk test were similar and oxygen did not significantly improve walk test outcomes, except oxygen saturation after the test (Table 3) .
Individual changes in dyspnea rating with oxygen and placebo air immediately after the 2 walk tests are shown in Table 4 . An improvement in dyspnea of 1 or more with ambulatory oxygen, which has been shown to be the minimal clinically important difference of the modified Borg scale [15] , was shown in 6 patients (33%) (patient nos. 4, 7, 9, 10, 13, and 17) and 8 patients (40%) (patient nos. 1, 2, 3, 7, 8, 9, 17, and 18) after the ordinary standardized 6-min walk test and the 6-min free walk test, respectively. On the other hand, worsening in dyspnea with oxygen was observed in 4 patients (20%) (patient nos. 8, 11, 12, and 14) and 5 patients (25%) (patient nos. 5, 12, 15, 16, and 20) after the ordinary and free walk tests, respectively.
Discussion
The current study is, to our knowledge, the first placebocontrolled, double-blind study with a crossover design that has examined the effect of ambulatory oxygen on exertional dyspnea in IPF. The results showed that ambulatory oxygen with a flow rate of 4 L/min did not improve dyspnea after a standardized 6-min walk test or after a 6-min free walk. Furthermore, oxygen did not cause significant improvement in walk distance, leg fatigue, or heart rate in both tests.
The effect of oxygen on dyspnea in COPD had been investigated in several studies [16e23] . Although oxygen improves exercise performance, its reported effects on dyspnea are conflicting. A Cochrane review demonstrated a statistically significant effect of oxygen on dyspnea in COPD patients without resting hypoxemia, but the effect size was marginal [24] . Recently, 2 randomized studies that tested the effect of oxygen on dyspnea in patients without resting hypoxemia were reported. However, the results showed that oxygen confers no benefit on daily dyspnea in COPD [25, 26] .
As for IPF, a few studies have examined the effect of oxygen. Only 1 randomized controlled trial reported a favorable effect of oxygen in interstitial lung disease [27] , but this study included patients with conditions other than IPF and the patient population comprised those with resting hypoxemia. Two recent studies showed conflicting results [28, 29] , but these were based on retrospective observations. Therefore, the present study is the first to test the effect of oxygen in a randomized controlled fashion specifically in IPF patients without resting hypoxemia. However, the results were negative.
The underlying mechanisms for dyspnea in restrictive lung diseases, such as IPF are complex and multi-factorial [30] . Not only oxygenation but also ventilatory demand, respiratory and peripheral muscle function, and cardiovascular factors can affect when patients feel dyspnea. This is also suggested by the fact that dyspnea rating assessed with the modified Borg scale ranged widely between extremities as shown in Table 4 , although the severity of disease was mild-to-moderate in every patient. The negative results in the present study suggest that desaturation is not the major factor for dyspnea in IPF as a whole, although more severe desaturation in IPF than in COPD has been reported [8] . Routine prescription of oxygen should be avoided because the effect of oxygen on dyspnea is not statistically significant and redundancy of ambulatory oxygen can worsen health-related quality of life of patients by leading them to be house-bound. Furthermore, inadequate use of domiciliary and ambulatory oxygen generates substantial costs.
It is interesting, however, that there were some patients whose dyspnea improved by more than 1 on the Borg scale with ambulatory oxygen, a change which has been considered to be clinically significant [15] . Three patients experienced an improvement in dyspnea of 2 or more on the modified Borg scale in the standardized 6-min walk test and the 6-min free walk test. These patients could be so-called responders. This result might mean that desaturation contributes to dyspnea greatly in selective patients and that these patients may benefit from ambulatory oxygen to alleviate dyspnea. Daily dyspnea has been reported to be the most important factor determining health-related quality of life in IPF [9] . In selected patients with IPF, even without resting hypoxemia, oxygen can reduce dyspnea and improve health-related quality of life. An assessment of the effect of oxygen should be undertaken individually before its prescription for the purpose of symptom relief in IPF patients without resting hypoxemia. However, it is difficult assess if oxygen has any effect by using placebo air in general practice. It might be, at least, necessary to make a comparison between walking with and without oxygen for evaluation of the effect of ambulatory oxygen on dyspnea and walk distance in practice, although a placebo effect cannot be fully excluded in this situation. We evaluated dyspnea after 2 types of the walk tests. Since the standardized 6-min walk test is considered to be a sub-maximal exercise test [13] , dyspnea after this walk test might not accurately reflect the dyspnea experienced in daily living. Therefore, we also evaluated dyspnea after a 6-min free walk, in which the patients walked at a pace that they used on a day to day basis; however, the result was the same as the standardized 6-min walk test. Although the short-term effect of oxygen on dyspnea was negative in the present study, its long-term effect on daily dyspnea should be investigated in further studies using both stationary and ambulatory oxygen.
This study has some limitations. First, the sample size was small. However, the number of patients was calculated so that a difference of 1 on the modified Borg scale would be detected with a statistical power of 80%. The detected differences in dyspnea were 0.2e0.6 in the current study. If more patients were recruited and statistical significance was reached, this small improvement in dyspnea is still less than the minimal clinically important difference and so is not practically relevant. Second, the small sample size from one center might have led to a selection bias. Third, adequate oxygenation was not maintained after the standardized 6-min walk test in the oxygen group, because the mean oxygen saturation immediately after the test was 84% even when using ambulatory oxygen. We used a flow rate of 4 L/min with a demand oxygen delivery system [11, 12] because a high flow rate was not practical. It is possible that a higher flow rate of oxygen might have led to a different result. However, given that oxygenation above 88% at 1 and 2 min after the standardized 6-min walk test and each point after the free walk test did not produce symptom relief, a positive effect of a higher rate of oxygen would be improbable. Finally, the patients consisted of those with mild-tomoderate functional impairments only. Two retrospective observational reports which showed conflicting results consisted of patients with moderate-to-severe impairments such as 51e58% of % predicted FVC and 25e32% of % predicted DLco, although these patients were without resting hypoxemia. The results from the present study may not be applied to severe patients; however, there may not be many patients who have severe impairment without resting hypoxemia.
In conclusion, this randomized controlled trial found that ambulatory oxygen provided no additional benefit over air in terms of dyspnea after an ordinary standardized 6-min walk test and a 6-min free walk in IPF patients. Our findings suggest that routine prescription of ambulatory oxygen for the purpose of symptom relief is not recommended in IPF patients without resting hypoxemia, even if they have exertional desaturation. However, some patients can benefit on an individual basis. An assessment of the effect of oxygen should be made individually before prescription.
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